SCHEMBL10240567

SCHEMBL10240567

CCc1ccc(Cl)c2nonc12

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
MAPT P10636 5/20 0.40
APAF1 O14727 1/20 0.40
TDP2 O95551 1/20 0.40
NSD2 O96028 1/20 0.40
THRB P10828 1/20 0.40
RECQL P46063 1/20 0.40
GALK1 P51570 1/20 0.40
BLM P54132 1/20 0.40
CASP6 P55212 1/20 0.40
SAE1 Q9UBE0 1/20 0.40
UBA2 Q9UBT2 1/20 0.40
CTRC Q99895 1/20 0.38
NPC1 O15118 4/20 0.35
TLR9 Q9NR96 3/20 0.35
KMT2A Q03164 2/20 0.35
ALDH1A1 P00352 4/20 0.35
HTT P42858 3/20 0.35
RAB9A P51151 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19269465 0.80 MAPT (0.42) GAAL3MBTL1MAPTAPAF1TDP2
SCHEMBL15257089 0.78 ELANE (0.37) GAAL3MBTL1MAPTCTRCNPC1
SCHEMBL24982527 0.76 MAPT (0.42) GAAL3MBTL1MAPTAPAF1TDP2
SCHEMBL10240415 0.72 TNF (0.39) GAAL3MBTL1MAPTAPAF1TDP2
SCHEMBL24299971 0.72 GSTP1 (0.38) NPC1
SCHEMBL10089701 0.71 GSTM2 (0.56) RECQLCASP6NPC1KMT2AALDH1A1
SCHEMBL22107972 0.71 G6PD (0.32) CASP6
SCHEMBL16029823 0.70 MAPT (0.36) GAAL3MBTL1MAPTAPAF1TDP2
SCHEMBL10305605 0.70 MAPT (0.36) GAAL3MBTL1MAPTAPAF1TDP2
SCHEMBL24115313 0.69 LMNA (0.36) GAAMAPTKMT2AALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007729-B1 SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS, THEIR PREPARATION AND USE IN MEDICAMENTS ESTEVE LABOR DR (ES) 2012-06-27 EP disclosed
US-20100331307-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS AGIOS PHARMACEUTICALS, INC. 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331307-A1 THERAPEUTIC COMPOUNDS AND COMPOSITIONS PDK1, PDK2, PDK3 GAA 1253/4885L3MBTL1 1664/4885MAPT 2867/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.